RDHLRedHill Biopharma Ltd.

Nasdaq redhillbio.com


$ 8.87 $ 0.17 (1.93 %)    

Wednesday, 04-Sep-2024 11:11:16 EDT
QQQ $ 460.65 $ -1.20 (-0.26 %)
DIA $ 410.44 $ 0.17 (0.04 %)
SPY $ 550.83 $ -1.13 (-0.2 %)
TLT $ 98.96 $ 1.26 (1.29 %)
GLD $ 230.43 $ 0.14 (0.06 %)
$ 8.72
$ 7.50 x 100
-- x --
-- - --
$ 6.43 - $ 82.00
74,819
na
444.61M
$ 1.39
$ 18.59
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 redhill-biopharma-announced-the-publication-of-data-in-journal-microorganisms-from-the-phase-23-study-of-opaganib-in-covid-19-pneumonia-that-showed-62-reduction-in-covid-19-mortality

Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19...

 redhill-biopharma-says-fda-granted-orphan-drug-designation-to-opaganib-for-treatment-of-neuroblastoma-a-type-of-childhood-cancer

Orphan Drug designation provides for a seven-year marketing exclusivity period should opaganib be approved in neuroblastoma and...

 redhill-biopharma-launched-talicia-omeprazole-magnesium-amoxicillin-and-rifabutin-in-the-united-arab-emirates-making-it-available-by-prescription-to-treat-adults-with-helicobacter-pylori-infection

The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, min...

 israel-based-redhills-investigational-covid-19-treatment-shows-encouraging-action-in-obesity-and-diabetes

RedHill Biopharma released study results showing opaganib's potential in treating Type 2 diabetes and obesity. The drug'...

 redhill-biopharmas-opaganib-demonstrates-impact-on-weight-and-glucose-in-preclinical-studies

RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today...

 redhill-biopharma-terminates-agreement-with-movantik-acquisition-valinor-pharma-and-hcr-redhill-and-received-99m-in-cash-and-gained-full-control-over-an-additional-074m-currently-held-in-restricted-account

In addition, the Agreement ends all existing credit ties with the Agreement parties, removes the existing lien against Talicia®...

 redhill-biopharma-terminates-license-agreement-for-aemcolo-a-treatment-for-travelers-diarrhea-will-be-officially-terminated-on-october-8-2024

RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today...

 redhill-biopharma-has-received-a-notice-of-allowance-for-its-us-patent-application-17900235-titled-biomarkers-of-coronavirus-pneumonia-for-treating-coronavirus-infection-or-preventing-diseases-caused-by-coronavirus-infection

https://patentcenter.uspto.gov/applications/17900235/ifw/docs

 redhill-announces-new-opaganib-chinese-patent-against-ebola-virus-valid-through-2035

RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION